{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:53:46Z","timestamp":1788998026181,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15877-8","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T23:34:14Z","timestamp":1775432054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prediction models for CAR-T Cell therapy-related adverse events in hematologic malignancies: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Linrui","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"4","key":"15877_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"2","key":"15877_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18(2):9\u201318.","journal-title":"Curr Hematol Malig Rep"},{"key":"15877_CR3","doi-asserted-by":"publisher","first-page":"950923","DOI":"10.3389\/fphar.2022.950923","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol. 2022;13:950923.","journal-title":"Front Pharmacol"},{"issue":"1","key":"15877_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","volume":"22","author":"W Luo","year":"2022","unstructured":"Luo W, Li C, Zhang Y, Du M, Kou H, Lu C, et al. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis. BMC Cancer. 2022;22(1):98.","journal-title":"BMC Cancer"},{"issue":"1","key":"15877_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41392-021-00764-4","volume":"6","author":"X Li","year":"2021","unstructured":"Li X, Shao M, Zeng X, Qian P, Huang H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal Transduct Target Ther. 2021;6(1):367.","journal-title":"Signal Transduct Target Ther"},{"key":"15877_CR6","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T cell-associated neurotoxicity. Front Immunol. 2020;11:577027.","journal-title":"Front Immunol"},{"issue":"9","key":"15877_CR7","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/neuonc\/noac034","volume":"24","author":"H Shalabi","year":"2022","unstructured":"Shalabi H, Martin S, Yates B, Wolters PL, Kaplan C, Smith H, et al. Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies. Neuro Oncol. 2022;24(9):1584\u201397.","journal-title":"Neuro Oncol"},{"issue":"12","key":"15877_CR8","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1007\/s00277-023-05477-y","volume":"102","author":"X Wang","year":"2023","unstructured":"Wang X, Li C, Luo W, Zhang Y, Huang Z, Xu J, et al. IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy. Ann Hematol. 2023;102(12):3575\u201385.","journal-title":"Ann Hematol"},{"key":"15877_CR9","doi-asserted-by":"publisher","first-page":"104134","DOI":"10.1016\/j.critrevonc.2023.104134","volume":"192","author":"GK Reynolds","year":"2023","unstructured":"Reynolds GK, Sim B, Spelman T, Thomas A, Longhitano A, Anderson MA, et al. Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2023;192:104134.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"15877_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","volume":"22","author":"JX Cao","year":"2020","unstructured":"Cao JX, Wang H, Gao WJ, You J, Wu LH, Wang ZX. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy. 2020;22(4):214\u201326.","journal-title":"Cytotherapy"},{"key":"15877_CR11","doi-asserted-by":"publisher","first-page":"e073538","DOI":"10.1136\/bmj-2022-073538","volume":"381","author":"KIE Snell","year":"2023","unstructured":"Snell KIE, Levis B, Damen JAA, Dhiman P, Debray TPA, Hooft L, et al. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538.","journal-title":"BMJ"},{"issue":"9","key":"15877_CR12","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1177\/0962280218785504","volume":"28","author":"TP Debray","year":"2019","unstructured":"Debray TP, Damen JA, Riley RD, Snell K, Reitsma JB, Hooft L, et al. A framework for meta-analysis of prediction model studies with binary and time-to-event outcomes. Stat Methods Med Res. 2019;28(9):2768\u201386.","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"15877_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"15877_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142(10):865\u201377.","journal-title":"Blood"},{"issue":"1","key":"15877_CR15","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M18-1377","volume":"170","author":"KGM Moons","year":"2019","unstructured":"Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1\u201333.","journal-title":"Ann Intern Med"},{"key":"15877_CR16","doi-asserted-by":"publisher","first-page":"i6460","DOI":"10.1136\/bmj.i6460","volume":"356","author":"TPA Debray","year":"2017","unstructured":"Debray TPA, Damen JAAG, Snell KIE, Ensor J, Hooft L, Reitsma JB, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ. 2017;356:i6460.","journal-title":"BMJ"},{"issue":"11","key":"15877_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1182\/blood.2024025910","volume":"145","author":"MS Nair","year":"2025","unstructured":"Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis Y, et al. Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Blood. 2025;145(11):1136\u201348.","journal-title":"Blood"},{"key":"15877_CR18","doi-asserted-by":"publisher","first-page":"987965","DOI":"10.3389\/fonc.2022.987965","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Song Z, Geng Y, Gao L, Xu L, Tang G, et al. The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy. Front Oncol. 2022;12:987965.","journal-title":"Front Oncol"},{"issue":"1","key":"15877_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","volume":"17","author":"P Sesques","year":"2024","unstructured":"Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024;17(1):61.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"15877_CR20","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood.2020010543","volume":"138","author":"K Rejeski","year":"2021","unstructured":"Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021;138(24):2499\u2013513.","journal-title":"Blood"},{"issue":"1","key":"15877_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16(1):88.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"15877_CR22","doi-asserted-by":"publisher","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","volume":"10","author":"K Rejeski","year":"2022","unstructured":"Rejeski K, Perez A, Iacoboni G, Penack O, B\u00fccklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer. 2022;10(5):e004475.","journal-title":"J Immunother Cancer"},{"key":"15877_CR23","doi-asserted-by":"crossref","unstructured":"Stella F, Pennisi M, Chiappella A, Casadei B, Bramanti S, Ljevar S et al. Prospective validation of CAR-HEMATOTOX and a simplified version predict survival in patients with large B-cell lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE Study. Transplant Cell Ther. 2025;31(4):240.e241-240.e249.","DOI":"10.1016\/j.jtct.2025.01.888"},{"issue":"1","key":"15877_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/hon.2931","volume":"40","author":"J Qi","year":"2022","unstructured":"Qi J, Lv X, Chen J, Wang H, Chu T, Tang Y, et al. TNF-\u03b1 increases the risk of bleeding in patients after CAR T\u2010cell therapy: a bleeding model based on a real\u2010world study of Chinese CAR T Working Party. Hematol Oncol. 2022;40(1):64\u201372.","journal-title":"Hematol Oncol"},{"issue":"1","key":"15877_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12859-024-05804-8","volume":"25","author":"Z Wei","year":"2024","unstructured":"Wei Z, Zhao C, Zhang M, Xu J, Xu N, Wu S, et al. PrCRS: a prediction model of severe CRS in CAR-T therapy based on transfer learning. BMC Bioinformatics. 2024;25(1):197.","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"15877_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bjh.18873","volume":"202","author":"L Zhou","year":"2023","unstructured":"Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: a multi\u2010centre study. Br J Haematol. 2023;202(3):517\u201324.","journal-title":"Br J Haematol"},{"key":"15877_CR27","doi-asserted-by":"publisher","first-page":"1450173","DOI":"10.3389\/fimmu.2024.1450173","volume":"15","author":"M Su","year":"2024","unstructured":"Su M, Chen L, Xie L, Fleurie A, Jonquieres R, Cao Q, et al. Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy. Front Immunol. 2024;15:1450173.","journal-title":"Front Immunol"},{"issue":"2","key":"15877_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/bloodadvances.2024014027","volume":"9","author":"S Zandaki Da, Selukar","year":"2025","unstructured":"Zandaki Da, Selukar S, Bi Y, Li Y, Zinsky M, Bonifant CL, et al. EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy. Blood Adv. 2025;9(2):270\u20139.","journal-title":"Blood Adv"},{"issue":"22","key":"15877_CR29","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.3390\/cancers15225443","volume":"15","author":"JW De Boer","year":"2023","unstructured":"De Boer JW, Keijzer K, Pennings ERA, Van Doesum JA, Spanjaart AM, Jak M, et al. Population-based external validation of the EASIX scores to predict CAR T-cell-related toxicities. Cancers. 2023;15(22):5443.","journal-title":"Cancers"},{"issue":"17","key":"15877_CR30","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5(17):3397\u2013406.","journal-title":"Blood Adv"},{"issue":"1","key":"15877_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.18596","volume":"201","author":"E Galli","year":"2023","unstructured":"Galli E, Sor\u00e0 F, Hohaus S, Fresa A, Pansini I, Autore F, et al. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells. Br J Haematol. 2023;201(1):86\u201394.","journal-title":"Br J Haematol"},{"issue":"10","key":"15877_CR32","doi-asserted-by":"publisher","first-page":"e009220","DOI":"10.1136\/jitc-2024-009220","volume":"12","author":"JH Frenking","year":"2024","unstructured":"Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK, et al. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma. J Immunother Cancer. 2024;12(10):e009220.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 1","key":"15877_CR33","doi-asserted-by":"publisher","first-page":"e14148","DOI":"10.1111\/tid.14148","volume":"25","author":"MT Czapka","year":"2023","unstructured":"Czapka MT, Riedell PA, Pisano JC. Infectious complications of CAR T-cell therapy: a longitudinal risk model. Transpl Infect Dis. 2023;25(Suppl 1):e14148.","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"15877_CR34","first-page":"404","volume":"30","author":"N Nakamura","year":"2024","unstructured":"Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, et al. Clinical impact of cytokine release syndrome on prolonged hematotoxicity after chimeric antigen receptor T cell therapy: KyoTox A-Score, a novel prediction model. Transpl Cell Ther. 2024;30(4):404\u201314.","journal-title":"Transpl Cell Ther"},{"key":"15877_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.thromres.2023.05.016","volume":"227","author":"Z Li","year":"2023","unstructured":"Li Z, Que Y, Wang D, Lu J, Li C, Xu M, et al. Recovery-model: a model for CAR T-cell-related thrombocytopenia in relapsed\/refractory multiple myeloma. Thromb Res. 2023;227:62\u201370.","journal-title":"Thromb Res"},{"issue":"1","key":"15877_CR36","doi-asserted-by":"publisher","first-page":"13641","DOI":"10.1038\/s41598-024-64466-x","volume":"14","author":"J Jung","year":"2024","unstructured":"Jung J, Kim JH, Bae JH, Woo SS, Lee H, Shin JY. A real-world pharmacovigilance study on cardiovascular adverse events of tisagenlecleucel using machine learning approach. Sci Rep. 2024;14(1):13641.","journal-title":"Sci Rep"},{"issue":"20","key":"15877_CR37","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1182\/bloodadvances.2020002592","volume":"4","author":"C Diorio","year":"2020","unstructured":"Diorio C, Shaw PA, Pequignot E, Orlenko A, Chen F, Aplenc R, et al. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Adv. 2020;4(20):5174\u201383.","journal-title":"Blood Adv"},{"issue":"1","key":"15877_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/NCC.0000000000001275","volume":"48","author":"K Zhao","year":"2025","unstructured":"Zhao K, Sun J, He M, Ruan H, Lin G, Shen N. A predictive model of severe cytokine release syndrome after coadministration of CD19- and CD22-chimeric antigen receptor T-cell therapy in children with B-cell hematological malignancies based on patient-reported outcomes. Cancer Nurs. 2025;48(1):3\u201311.","journal-title":"Cancer Nurs"},{"issue":"14","key":"15877_CR39","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021;5(14):2799\u2013806.","journal-title":"Blood Adv"},{"key":"15877_CR40","doi-asserted-by":"crossref","unstructured":"Zeng F, Zhang H, Wang S, Passang T, Li Y, Funk CR et al. Plasma cytokine and chemokine profiles predict efficacy and toxicity of anti-CD19 CAR-T cell therapy in large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2025;25(7):e474-e486.e478.","DOI":"10.1016\/j.clml.2025.02.009"},{"issue":"12","key":"15877_CR41","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","volume":"77","author":"DB Rubin","year":"2020","unstructured":"Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 2020;77(12):1536\u201342.","journal-title":"JAMA Neurol"},{"issue":"3","key":"15877_CR42","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/bloodadvances.2024014455","volume":"9","author":"EC Liang","year":"2025","unstructured":"Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, et al. Development and validation of predictive models of early immune effector cell\u2013associated hematotoxicity. Blood Adv. 2025;9(3):606\u201316.","journal-title":"Blood Adv"},{"issue":"11","key":"15877_CR43","doi-asserted-by":"publisher","first-page":"e005459","DOI":"10.1136\/jitc-2022-005459","volume":"10","author":"Y Amidi","year":"2022","unstructured":"Amidi Y, Eckhardt CA, Quadri SA, Malik P, Firme MS, Jones DK, et al. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. J Immunother Cancer. 2022;10(11):e005459.","journal-title":"J Immunother Cancer"},{"key":"15877_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.11.004","volume":"65","author":"S Lesch","year":"2020","unstructured":"Lesch S, Benmebarek M-R, Cadilha BL, Stoiber S, Subklewe M, Endres S, et al. Determinants of response and resistance to CAR T cell therapy. Semin Cancer Biol. 2020;65:80\u201390.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"15877_CR45","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1177\/0962280214558972","volume":"26","author":"PC Austin","year":"2017","unstructured":"Austin PC, Steyerberg EW. Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models. Stat Methods Med Res. 2017;26(2):796\u2013808.","journal-title":"Stat Methods Med Res"},{"key":"15877_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/1471-2288-14-137","volume":"14","author":"T van der Ploeg","year":"2014","unstructured":"van der Ploeg T, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints. BMC Med Res Methodol. 2014;14:137.","journal-title":"BMC Med Res Methodol"},{"key":"15877_CR47","doi-asserted-by":"publisher","first-page":"105449","DOI":"10.1016\/j.compbiomed.2022.105449","volume":"145","author":"R Rios","year":"2022","unstructured":"Rios R, Miller RJH, Manral N, Sharir T, Einstein AJ, Fish MB, et al. Handling missing values in machine learning to predict patient-specific risk of adverse cardiac events: insights from REFINE SPECT registry. Comput Biol Med. 2022;145:105449.","journal-title":"Comput Biol Med"},{"issue":"7","key":"15877_CR48","doi-asserted-by":"publisher","first-page":"e202300368","DOI":"10.1002\/bimj.202300368","volume":"66","author":"E Kipruto","year":"2024","unstructured":"Kipruto E, Sauerbrei W. Post-estimation shrinkage in full and selected linear regression models in low-dimensional data revisited. Biom J. 2024;66(7):e202300368.","journal-title":"Biom J"},{"key":"15877_CR49","doi-asserted-by":"publisher","first-page":"111732","DOI":"10.1016\/j.jclinepi.2025.111732","volume":"181","author":"T Kaul","year":"2025","unstructured":"Kaul T, Damen JAA, Wynants L, Van Calster B, van Smeden M, Hooft L, et al. Assessing the quality of prediction models in health care using the Prediction model Risk Of Bias ASsessment Tool (PROBAST): an evaluation of its use and practical application. J Clin Epidemiol. 2025;181:111732.","journal-title":"J Clin Epidemiol"},{"key":"15877_CR50","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.","journal-title":"BMJ"},{"key":"15877_CR51","doi-asserted-by":"publisher","first-page":"e078276","DOI":"10.1136\/bmj-2023-078276","volume":"386","author":"O Efthimiou","year":"2024","unstructured":"Efthimiou O, Seo M, Chalkou K, Debray T, Egger M, Salanti G. Developing clinical prediction models: a step-by-step guide. BMJ. 2024;386:e078276.","journal-title":"BMJ"},{"issue":"7","key":"15877_CR52","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"15877_CR53","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/TA.0000000000004584","volume":"98","author":"T Garwe","year":"2025","unstructured":"Garwe T, Choi J. An introduction to clinical prediction models using logistic regression in acute care surgery research: methodologic considerations and common pitfalls. J Trauma Acute Care Surg. 2025;98(5):699\u2013703.","journal-title":"J Trauma Acute Care Surg"},{"issue":"4","key":"15877_CR54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4097\/kja.25001","volume":"78","author":"GJ Choi","year":"2025","unstructured":"Choi GJ, Kang H. Heterogeneity in meta-analyses: an unavoidable challenge worth exploring. Korean J Anesthesiol. 2025;78(4):301\u201314.","journal-title":"Korean J Anesthesiol"},{"key":"15877_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN B, JN K","year":"2019","unstructured":"JN B, JN K. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"1","key":"15877_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12874-018-0613-8","volume":"18","author":"T Greg\u00f3rio","year":"2018","unstructured":"Greg\u00f3rio T, Pipa S, Cavaleiro P, Atan\u00e1sio G, Albuquerque I, Chaves PC, et al. Prognostic models for intracerebral hemorrhage: systematic review and meta-analysis. BMC Med Res Methodol. 2018;18(1):145.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"15877_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/hepr.13966","volume":"54","author":"N Kimura","year":"2024","unstructured":"Kimura N, Takahashi K, Setsu T, Horibata Y, Kaneko Y, Miyazaki H, et al. Development and validation of machine learning model for predicting treatment responders in patients with primary biliary cholangitis. Hepatol Res. 2024;54(1):67\u201377.","journal-title":"Hepatol Res"},{"key":"15877_CR58","doi-asserted-by":"publisher","first-page":"877477","DOI":"10.3389\/fimmu.2022.877477","volume":"13","author":"F Korell","year":"2022","unstructured":"Korell F, Penack O, Mattie M, Schreck N, Benner A, Krzykalla J, et al. EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-a cohort study. Front Immunol. 2022;13:877477.","journal-title":"Front Immunol"},{"issue":"1","key":"15877_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-022-00777-4","volume":"13","author":"AA Acosta-Medina","year":"2023","unstructured":"Acosta-Medina AA, Johnson IM, Bansal R, Hathcock M, Kenderian SJ, Durani U, et al. Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma. Blood Cancer J. 2023;13(1):7.","journal-title":"Blood Cancer J"},{"key":"15877_CR60","doi-asserted-by":"crossref","unstructured":"Park L, Tsai YT, Lim HK, Faulhaber LD, Burleigh K, Faulhaber EM et al. Cytokine-mediated increase in endothelial-leukocyte interaction mediates brain capillary plugging during CAR T cell neurotoxicity. bioRxiv [Preprint]. 2025:02.19.638920.","DOI":"10.1101\/2025.02.19.638920"},{"issue":"8","key":"15877_CR61","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1007\/s00259-024-06667-0","volume":"51","author":"J Gui","year":"2024","unstructured":"Gui J, Li M, Xu J, Zhang X, Mei H, Lan X. [(18)F]FDG PET\/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy. Eur J Nucl Med Mol Imaging. 2024;51(8):2308\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"15877_CR62","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13550-024-01172-9","volume":"14","author":"B Ferrer-Lores","year":"2024","unstructured":"Ferrer-Lores B, Ortiz-Algarra A, Pic\u00f3-Peris A, Estepa-Fern\u00e1ndez A, Bellv\u00eds-Bataller F, Weiss GJ, et al. Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model. EJNMMI Res. 2024;14(1):113.","journal-title":"EJNMMI Res"},{"issue":"10","key":"15877_CR63","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/acn3.51866","volume":"10","author":"CA Eckhardt","year":"2023","unstructured":"Eckhardt CA, Sun H, Malik P, Quadri S, Santana Firme M, Jones DK, et al. Automated detection of immune effector cell-associated neurotoxicity syndrome via quantitative EEG. Ann Clin Transl Neurol. 2023;10(10):1776\u201389.","journal-title":"Ann Clin Transl Neurol"},{"issue":"19","key":"15877_CR64","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898\u2013911.","journal-title":"Blood Adv"},{"issue":"15","key":"15877_CR65","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/cancers13153912","volume":"13","author":"W Lei","year":"2021","unstructured":"Lei W, Xie M, Jiang Q, Xu N, Li P, Liang A, et al. Treatment-related adverse events of chimeric antigen receptor T-cell (CAR T) in clinical trials: a systematic review and meta-analysis. Cancers. 2021;13(15):3912.","journal-title":"Cancers"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15877-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T01:02:13Z","timestamp":1779066133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15877-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15877"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15877-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Protocol of this study was registered at PROSPERO (CRD420251062713) since 28\/5\/2025. Amendment was submitted and has been approved on 9\/8\/2025. None reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"624"}}